© 2021 MJH Life Sciences™ and Optometry Times. All rights reserved.
Pipeline: New therapies to come for debilitating eye diseases
November 12, 2020
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director , Bernard Gilly, PhD
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director
Bernard Gilly, PhD
CEO, Gensight Biologics
New drug from Gensight Biologics hits pipeline
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Related: Myopia control data and whats to come with Dr. Noel Brennan
Related Content:
